Breakthrough status with FDA – Duplicate – [#1] – Duplicate – [#303]
The FDA has documented the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults during the early stages of treatment with antidepressants. The pooled analysis of short-term clinical trials showed this risk specifically for those aged 18-24, particularly in patients with major depressive disorder (MDD) and other psychiatric conditions.
Breakthrough status with FDA – Duplicate – [#1]
The FDA has documented the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults during the early stages of treatment with antidepressants. The pooled analysis of short-term clinical trials showed this risk specifically for those aged 18-24, particularly in patients with major depressive disorder (MDD) and other psychiatric conditions.